{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:13:44Z","timestamp":1780586024654,"version":"3.54.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T00:00:00Z","timestamp":1776729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01737-7","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T17:44:22Z","timestamp":1776793462000},"page":"2979-2996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Use of Baricitinib in Patients with Atopic Dermatitis in Spain: DAMA-S Study, A Retrospective Chart Review"],"prefix":"10.1007","volume":"16","author":[{"given":"Enrique","family":"G\u00f3mez de la Fuente","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I\u00f1igo","family":"Martinez-Espronceda Esquerdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Vidal Sarr\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignasi","family":"Figueras-Nart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Silvestre Salvador","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolanda","family":"Gilaberte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Santos Alarc\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Serra-Baldrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Munera Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa M.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"D\u00edaz-Cerezo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Moyano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Talavera-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,21]]},"reference":[{"key":"1737_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.33590\/emjdermatol\/10312649","volume":"1","author":"SVS Siedlikowski","year":"2019","unstructured":"Siedlikowski SVS, Lynde C. Treatment of atopic dermatitis using JAK inhibitors: a systematic review. EMJ Dermatol. 2019;1:89\u2013100.","journal-title":"EMJ Dermatol"},{"issue":"6","key":"1737_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/j.anai.2017.09.076","volume":"119","author":"PP Vakharia","year":"2017","unstructured":"Vakharia PP, Chopra R, Sacotte R, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol. 2017;119(6):548-52 e3.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"1737_CR3","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1111\/all.13401","volume":"73","author":"S Barbarot","year":"2018","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393.","journal-title":"Allergy"},{"issue":"9","key":"1737_CR4","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1737_CR5","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116\u201332.","journal-title":"J Am Acad Dermatol"},{"key":"1737_CR6","unstructured":"European Medicines Agency. Olumiant 2024. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/olumiant. Accessed Sept 2025."},{"issue":"12","key":"1737_CR7","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","volume":"156","author":"K Reich","year":"2020","unstructured":"Reich K, Kabashima K, Peris K, et al. Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(12):1333\u201343.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"1737_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jaad.2021.02.028","volume":"85","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Forman S, Silverberg JI, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis: results from a randomized monotherapy phase\u00a03 trial in the United States and Canada (BREEZE-AD5). J Am Acad Dermatol. 2021;85(1):62\u201370.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"1737_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/bjd.18898","volume":"183","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase\u00a0III trials. Br J Dermatol. 2020;183(2):242\u201355.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1737_CR10","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/jdv.16948","volume":"35","author":"T Bieber","year":"2021","unstructured":"Bieber T, Thyssen JP, Reich K, et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J Eur Acad Dermatol Venereol. 2021;35(2):476\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1737_CR11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","volume":"10","author":"JM Hanifin","year":"2001","unstructured":"Hanifin JM, Thurston M, Omoto M, et al. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 2001;10(1):11\u20138.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1737_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/jdv.20248","volume":"39","author":"ME Jacobson","year":"2025","unstructured":"Jacobson ME, Morimoto RY, Leshem YA, et al. The Eczema Area and Severity Index: an update of progress and challenges in its measurement of atopic dermatitis after 20\u00a0years of use. J Eur Acad Dermatol Venereol. 2025;39(1):70\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"1737_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jaad.2020.04.104","volume":"83","author":"E Simpson","year":"2020","unstructured":"Simpson E, Bissonnette R, Eichenfield LF, et al. the Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis. J Am Acad Dermatol. 2020;83(3):839\u201346.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1737_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s41687-020-00265-y","volume":"4","author":"C Dias-Barbosa","year":"2020","unstructured":"Dias-Barbosa C, Matos R, Vernon M, Carney CE, Krystal A, Puelles J. Content validity of a sleep numerical rating scale and a sleep diary in adults and adolescents with moderate-to-severe atopic dermatitis. J Patient-Report Outcomes. 2020;4(1):100.","journal-title":"J Patient-Report Outcomes"},{"issue":"4","key":"1737_CR15","doi-asserted-by":"publisher","first-page":"1512","DOI":"10.1007\/s12325-024-02802-3","volume":"41","author":"A Rams","year":"2024","unstructured":"Rams A, Baldasaro J, Bunod L, et al. Assessing itch severity: content validity and psychometric properties of a patient-reported pruritus numeric rating scale in atopic dermatitis. Adv Ther. 2024;41(4):1512\u201325.","journal-title":"Adv Ther"},{"key":"1737_CR16","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.1088","volume":"102","author":"D Rogner","year":"2022","unstructured":"Rogner D, Biedermann T, Lauffer F. Treatment of atopic dermatitis with baricitinib: first real-life experience. Acta Derm Venereol. 2022;102:adv00677.","journal-title":"Acta Derm Venereol"},{"key":"1737_CR17","doi-asserted-by":"crossref","unstructured":"Navarro-Trivi\u00f1o FJ, Gal\u00e1n-Guti\u00e9rrez M, Pereyra-Rodr\u00edguez JJ, Ruiz-Villaverde R. Real-world safety and efficacy profile of baricitinib in patients with atopic dermatitis: a multicenter retrospective trial from four spanish hospitals in Andalusia. Actas Dermosifiliogr. 2024;115(10):T1054\u2013T1057.","DOI":"10.1016\/j.ad.2024.10.053"},{"issue":"4","key":"1737_CR18","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/1346-8138.16350","volume":"49","author":"A Uchiyama","year":"2022","unstructured":"Uchiyama A, Fujiwara C, Inoue Y, Motegi SI. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: a single-center retrospective study. J Dermatol. 2022;49(4):469\u201371.","journal-title":"J Dermatol"},{"key":"1737_CR19","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.3978","volume":"102","author":"CM Boesjes","year":"2022","unstructured":"Boesjes CM, Kamphuis E, Zuithoff NPA, et al. Daily practice experience of baricitinib treatment for patients with difficult-to-treat atopic dermatitis: results from the BioDay Registry. Acta Derm Venereol. 2022;102:adv00820.","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"1737_CR20","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.jaip.2024.04.008","volume":"12","author":"YT Cho","year":"2024","unstructured":"Cho YT, Lee MS, Chang WY, Lu YT, Chu CY, Chan TC. Comprehensive real-world comparisons between baricitinib and dupilumab treatments for moderate to severe atopic dermatitis. J Allergy Clin Immunol Pract. 2024;12(7):1924-7.e1.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"1737_CR21","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1684\/ejd.2023.4618","volume":"33","author":"A De Greef","year":"2023","unstructured":"De Greef A, Ghislain PD, Baeck M. Prolonged real-life experience with baricitinib in patients with moderate-to-severe atopic dermatitis. Eur J Dermatol. 2023;33(6):707\u20139.","journal-title":"Eur J Dermatol"},{"issue":"1","key":"1737_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40261-023-01335-x","volume":"44","author":"E Freitas","year":"2024","unstructured":"Freitas E, Paiva Lopes MJ, Cruz MJ, et al. Real-world effectiveness and safety of baricitinib in patients with atopic dermatitis. Clin Drug Investig. 2024;44(1):87\u201390.","journal-title":"Clin Drug Investig"},{"key":"1737_CR23","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v103.14153","volume":"103","author":"Z Reguiai","year":"2023","unstructured":"Reguiai Z, Becherel PA, Perrot JL, et al. Impact of baricitinib on patients\u2019 quality of life after one year of treatment for atopic dermatitis in real-world practice: results of the Observatory of Chronic Inflammatory Skin Diseases Registry. Acta Derm Venereol. 2023;103:adv14153.","journal-title":"Acta Derm Venereol"},{"issue":"8","key":"1737_CR24","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1007\/s12325-023-02528-8","volume":"40","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, de Bruin-Weller M, Costanzo A, et al. Baseline body surface area and itch severity define response to baricitinib in patients with moderate-to-severe atopic dermatitis at week\u00a016. Adv Ther. 2023;40(8):3574\u201387.","journal-title":"Adv Ther"},{"issue":"4","key":"1737_CR25","doi-asserted-by":"publisher","first-page":"e543","DOI":"10.1111\/jdv.18804","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Elberling J, Skov L, et al. Short-term real-world experience with baricitinib treatment in Danish adults with moderate-severe atopic dermatitis. J Eur Acad Dermatol Venereol. 2023;37(4):e543\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1737_CR26","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1016\/j.jaad.2022.10.034","volume":"88","author":"J Vanlerberghe","year":"2023","unstructured":"Vanlerberghe J, Dezoteux F, Martin C, et al. Effectiveness and tolerance of Janus kinase inhibitors for the treatment of recalcitrant atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2023;88(4):900\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1737_CR27","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s13555-021-00534-8","volume":"11","author":"T Buhl","year":"2021","unstructured":"Buhl T, Rosmarin D, Serra-Baldrich E, et al. Itch and sleep improvements with baricitinib in patients with atopic dermatitis: a post hoc analysis of 3 phase\u00a03 studies. Dermatol Ther (Heidelb). 2021;11(3):971\u201382.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1737_CR28","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","volume":"121","author":"JI Silverberg","year":"2018","unstructured":"Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121(3):340\u20137.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1737_CR29","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1111\/jdv.15919","volume":"34","author":"M Augustin","year":"2020","unstructured":"Augustin M, Langenbruch A, Blome C, et al. Characterizing treatment-related patient needs in atopic eczema: insights for personalized goal orientation. J Eur Acad Dermatol Venereol. 2020;34(1):142\u201352.","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01737-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01737-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:49Z","timestamp":1780584829000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01737-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,21]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1737"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01737-7","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,21]]},"assertion":[{"value":"24 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Enrique G\u00f3mez de la Fuente has received speaker honoraria, and support for attending meeting and\/or travel from Lilly, Abbvie, Sanofi, Pfizer, and Leo Pharma; and has participated on a data safety monitoring board (DSMB) or advisory board for Lilly, Abbvie, Sanofi, and Pfizer. At the time of the study, Enrique G\u00f3mez de la Fuente worked at Hospital Fundaci\u00f3n Alcorc\u00f3n (Madrid, Spain). His current affiliation is Hospital Ram\u00f3n y Cajal (Madrid, Spain). David Vidal Sarr\u00f3 has received consulting fees and speaker honoraria from Lilly. Ignasi Figueras-Nart has received consulting fees, speaker honoraria, and support for attending meetings and\/or travel from Lilly, Novartis, Sanofi, Abbvie, Leo Pharma, Vifor Pharma, and Pfizer. Juan F. Silvestre Salvador has received consulting fees from AbbVie, Almirall-Hermal, Lilly, Galderma, Leo Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; speaker honoraria and participated on a DSMB or Advisory Board for AbbVie, Almirall-Hermal, Lilly, Galderma, LEO Pharma, Pfizer and Sanofi-Genzyme; and support for attending meetings and\/or travel from AbbVie, Almirall-Hermal, Lilly, Pfizer and Sanofi-Genzyme. Yolanda Gilaberte received consulting fees from Lilly, Cantabria Labs, Leo Pharma, Isdin, UCB and Almirall; received speaker honoraria from Sanofi, Pfizer, Abbvie, Cantabria Labs, Eucerin, Lilly, Leo Pharma and Incyte; support for attending meeting and\/or travel from Sanofi and Eucerin; and has acted as leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid for the European Academy of Dermatology and Virology (EADV) and the European Society of Photodermatology. Sergio Santos Alarc\u00f3n has received speaker honoraria, and payment for expert testimony from; and has participated on a DSMB or Advisory Board for Almirall, Abbvie, Amgen, Pfizer, Novartis, Janssen-Cilag, Lilly, Leo Pharma, UCB Pharma, Pierre Fabre, Isdin, and Sanofi. Esther Serra-Baldrich has received grants or contracts from Galderma, Sanofi, Incyte and Leo Pharma; speaker honoraria from Sanofi, Galderma, Pfizer, Abbvie, Lilly and Leo Pharma; support for attending meeting and\/or travel from Sanofi and Pfizer; and has participated on a DSMB or Advisory Board for Sanofi, Galderma, Pfizer, Abbvie, Lilly, and Leo Pharma. Rosa M. Moro, Silvia D\u00edaz-Cerezo, Sebasti\u00e1n Moyano and Mercedes N\u00fa\u00f1ez are full time employees at Lilly and minor owners of Lilly shares. Enrique Herrera, I\u00f1igo Mart\u00ednez-Espronceda Esquerdo, M\u00f3nica Munera Campos and Irene Talavera-Rodr\u00edguez declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The study was designed and conducted in accordance with the ethical principles set out in the Declaration of Helsinki and was approved by the Hospital Universitario Fundaci\u00f3n Alcorc\u00f3n Ethics Committee (Code 23\/58). All patients provided written informed consent for the collection of their medical data and its use as part of this observational research study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}